NCT06776757View on ClinicalTrials.gov

Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 25, 2023

Primary Completion Date

June 25, 2025

Study Completion Date

December 25, 2025

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI)

Sintilimab (100mg,150mg, 200mg; Q3W) +Cetuximab (500mg/m²,Q2W)+Chemotherapy（mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI）

DRUG

Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI)

Sintilimab (Based on Phase 1b recommended dose; Q3W) +Cetuximab (500mg/m²,Q2W)+Chemotherapy（mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI）

Trial Locations (1)

518116

RECRUITING

National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital & Shenzhen Hospital, Shenzhen

All Listed Sponsors
lead

Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center

OTHER